Drugs

Andrew Armstrong: Pleased to share our ARCHES analysis of efficacy, safety, and QOL of enza/ADT in men w/mHSPC by age

Photo of Andrew Armstrong taken from goodrx.com

Dec 15, 2023, 06:25

Andrew Armstrong: Pleased to share our ARCHES analysis of efficacy, safety, and QOL of enza/ADT in men w/mHSPC by age

Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology at the Duke Cancer Institute, shared on X/Twitter:

“Pleased to share our ARCHES analysis of efficacy, safety, and quality of life of enzalutamide (ENZA)/androgen-deprivation therapy (ADT) in men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) by age (>75 vs <75) in the European Urology Oncology journal.”

For the article, click here.
Source: Andrew Armstrong/X

Andrew Armstrong androgen-deprivation therapy (ADT) ARCHES cancer Duke Cancer Institute enzalutamide (ENZA) European Urology Oncology Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) OncoDaily Oncology

ACT for Children: Tackling Inequities in Childhood Cancer Through Unique Global Collaboration

Richard Gere and Alejandra Gere to Join Second Global OncoThon on February 15 for Fight Against Childhood Cancer

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%